Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, double-blind, randomized, placebo-controlled study of DYSPORT AESTHETIC for use in the temporary improvement in the appearance of moderate to severe lateral canthal lines (LCLs) at maximum smile

Next Previous
Trial Profile

A Phase III, double-blind, randomized, placebo-controlled study of DYSPORT AESTHETIC for use in the temporary improvement in the appearance of moderate to severe lateral canthal lines (LCLs) at maximum smile

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Facial wrinkles
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 04 Sep 2018 New trial record
  • 14 Aug 2018 According to a Galderma media release, Health Canada has approved DYSPORT AESTHETIC (abobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow's feet) in adult patients, based on the data from this trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top